Biotech giant Biogen has unveiled encouraging results from early-stage trials of salanersen, an experimental candidate designed to succeed its flagship SMA drug, Spinraza.
Clinical findings and neuroprotective effects Latest data from a cohort of 24 children aged six months to 12 years—who had previously undergone gene therapy—demonstrated a 75% reduction in neurofilament light chain levels, a key biomarker for neurodegeneration. Remarkably, half of the participants achieved significant motor milestones based on World Health Organization (WHO) standards, showing improvements in fundamental tasks such as sitting, standing, or walking independently.
Technical superiority and dosing advantages Developed as a more potent antisense oligonucleotide, salanersen functions by correcting gene splicing to boost the production of survival motor neuron proteins. A major competitive edge for this new therapy is its streamlined dosing schedule; it is designed for once-yearly administration, a significant reduction compared to the three-times-yearly regimen required by existing treatments.
Strategic roadmap for late-stage development Biogen has initiated the screening process for its Phase 3 clinical program. The upcoming late-stage study will consist of three separate trials targeting diverse patient populations: newborns, infants previously treated with gene therapy, and adolescents or adults who are either treatment-naive or switching from other SMA medications.
Market analysts suggest that salanersen’s “convenient” dosing and its effectiveness in patients who have already received other therapies could secure Biogen’s leadership in the SMA landscape through the 2030s, offering a vital option for those with unmet medical needs.